Abstract Background A previous European Headache Federation (EHF) guideline
addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide …

Migraine is an extremely disabling, common neurological disorder characterized by a
complex neurobiology, involving a series of central and peripheral nervous system areas …

Objective To incorporate recent research findings, expert consensus, and patient
perspectives into updated guidance on the use of new acute and preventive treatments for …

Background Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor
have shown efficacy in the prevention of migraine attacks. We investigated the efficacy and …

Migraine is a complex neurovascular disease with a range of severity and symptoms, yet
mostly studied as one phenotype in genome-wide association studies (GWAS). Here we …

Background A substantial proportion of patients with migraine does not respond to, or
cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody …

Migraine is one of the most prevalent and disabling diseases worldwide, but until recently,
few migraine-specific therapies had been developed. Extensive basic and clinical scientific …

Importance Approximately 90% of people in the US experience headache during their
lifetime. Migraine is the second leading cause of years lived with disability worldwide …

Background Direct comparisons of the tolerability and safety of migraine preventive
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …

Background Several novel treatments targeting the calcitonin gene-related peptide pathway
have been developed for migraine. We evaluated the efficacy of these medications …